These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19281920)

  • 1. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial.
    Brilakis ES; Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Haagen D; Saeed B; Gadiparthi C; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
    J Am Coll Cardiol; 2009 Mar; 53(11):919-28. PubMed ID: 19281920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial.
    Brilakis ES; Lichtenwalter C; Abdel-karim AR; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S
    JACC Cardiovasc Interv; 2011 Feb; 4(2):176-82. PubMed ID: 21349456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: insights from the SOS (stenting of saphenous vein grafts) trial.
    Lichtenwalter C; de Lemos JA; Roesle M; Obel O; Holper EM; Haagen D; Saeed B; Iturbe JM; Shunk K; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S; Brilakis ES
    JACC Cardiovasc Interv; 2009 Sep; 2(9):855-60. PubMed ID: 19778774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions.
    Wöhrle J; Nusser T; Kestler HA; Kochs M; Hombach V
    Clin Res Cardiol; 2007 Feb; 96(2):70-6. PubMed ID: 17146605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study.
    Hoffmann R; Pohl T; Köster R; Blindt R; Boeckstegers P; Heitzer T
    Heart; 2007 Mar; 93(3):331-4. PubMed ID: 16940392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial.
    Stone GW; Goldberg S; O'Shaughnessy C; Midei M; Siegel RM; Cristea E; Dangas G; Lansky AJ; Mehran R
    JACC Cardiovasc Interv; 2011 Mar; 4(3):300-9. PubMed ID: 21435608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent cardiovascular events with paclitaxel-eluting versus bare-metal stents in saphenous vein graft lesions: insights from the SOS (Stenting of Saphenous Vein Grafts) trial.
    Michael TT; Abdel-karim AR; Papayannis A; Lichtenwalter C; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger PB; Banerjee S; Brilakis ES
    J Invasive Cardiol; 2011 Jun; 23(6):216-9. PubMed ID: 21646644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Van den Branden F; Van Langenhove G;
    J Am Coll Cardiol; 2007 Jul; 50(3):261-7. PubMed ID: 17631219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction.
    Stone GW; Lansky AJ; Pocock SJ; Gersh BJ; Dangas G; Wong SC; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Möckel M; Ochala A; Kellock A; Parise H; Mehran R;
    N Engl J Med; 2009 May; 360(19):1946-59. PubMed ID: 19420364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
    Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
    Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel-eluting stents reduce neointimal hyperplasia compared to bare metal stents in saphenous vein grafts: intravascular ultrasonography analysis of the SOS (Stenting of Saphenous Vein Grafts) trial.
    Jeroudi OM; Abdel-Karim AR; Michael TT; Lichtenwalter C; de Lemos JA; Obel O; Addo T; Roesle M; Haagen D; Rangan BV; Raghunathan D; DaSilva M; Saeed B; Bissett JK; Sachdeva R; Voudris VV; Karyofillis P; Kar B; Rossen J; Fasseas P; Berger P; Banerjee S; Brilakis ES
    EuroIntervention; 2011 Dec; 7(8):948-54. PubMed ID: 22157480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome.
    Ge L; Iakovou I; Sangiorgi GM; Chieffo A; Melzi G; Cosgrave J; Montorfano M; Michev I; Airoldi F; Carlino M; Corvaja N; Colombo A
    J Am Coll Cardiol; 2005 Apr; 45(7):989-94. PubMed ID: 15808752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.